Press releases about „rcc“ sorted by

Date of release

• Date of release
• Relevance

Search: press release rcc

Webinar Series: Challenges of the Nuclear Sector

• 2020-11-06
• Software
• ESI Group

In a global context of energy transition towards a low-carbon society, each stakeholder faces a arduous challenge to achieve innovation, performance and safety and all the while complying with governmental standards in to provide the best time to market. With 45 years experience in Virtual Prototyping, ESI Group provides qualified digital solutions... go to the press release

---

Search: press release rcc

4SC AG: First Patient Enrolled in MERKLIN 2 Study

• 2020-10-21
• Research / Development
• 4SC AG

Combination of domatinostat (HDAC inhibitor) and checkpoint inhibitor avelumab (anti-PD-L1 antibody) to be investigated in Merkel cell carcinoma (MERKLIN 2 study) 4SC AG (4SC, FSE Prime Standard: VSC) today announced that the first patient has been enrolled in the MERKLIN 2 study investigating the combination of 4SC's selective HDAC class I inhibitor... go to the press release

---

Search: press release rcc

4SC AG: Einschluss des ersten Patienten in die MERKLIN 2-Studie

• 2020-10-21
• Research / Development
• 4SC AG

Kombination von Domatinostat (HDAC Inhibitor) und Checkpoint-Inhibitor Avelumab (anti-PD-L1-Antikörper) wird beim Merkelzellkarzinom untersucht (MERKLIN 2-Studie) Die 4SC AG (4SC, FSE Prime Standard: VSC) hat heute bekannt gegeben, dass der erste Patient in die MERKLIN 2-Studie zur Untersuchung der Kombination von 4SC's selektivem HDAC-Klasse I-Inhibitor... go to the press release

---

Search: press release rcc

4SC AG: Poster presentation at the ESMO Virtual Congress 2020

• 2020-09-17
• Pharmaceutics
• 4SC AG

4SC AG (4SC, FSE Prime Standard: VSC) today announced that a Trial in Progress poster entitled: 1153TiP - A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab (BAVENCIO®) in patients with advanced unresectable/metasta­tic Merkel Cell Carcinoma (MCC) progressing on anti-PD-(L)1 antibody therapy... go to the press release

---

Search: press release rcc

4SC AG: Posterpräsentation auf dem ESMO Virtual Congress 2020

• 2020-09-17
• Pharmaceutics
• 4SC AG

Die 4SC AG (4SC, FSE Prime Standard: VSC) gab heute bekannt, dass ein Trial in Progress-Poster mit dem Titel: 1153TiP - A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab (BAVENCIO®) in patients with advanced unresectable/metasta­tic Merkel Cell Carcinoma (MCC) progressing on anti-PD-(L)1... go to the press release

---

Search: press release rcc

4SC AG: 4SC expands avelumab supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer

• 2020-09-15
• Research / Development
• 4SC AG

Combination of domatinostat (HDAC inhibitor) and checkpoint inhibitor avelumab (anti-PD-L1 antibody) to be investigated in a second clinical study in Merkel cell carcinoma (MERKLIN 1 study) 4SC AG (4SC, FSE Prime Standard: VSC) today announced that it has entered into an extension of the supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer... go to the press release

---

Search: press release rcc

4SC AG: 4SC erweitert Liefervereinbarung mit Merck KGaA, Darmstadt, Germany und Pfizer

• 2020-09-15
• Research / Development
• 4SC AG

Kombination von Domatinostat (HDAC Inhibitor) und Checkpoint-Inhibitor Avelumab (anti-PD-L1-Antikörper) soll in einer zweiten klinischen Studie im Merkelzellkarzinom untersucht werden (MERKLIN 1-Studie) Die 4SC AG (4SC, FWB Prime Standard: VSC) hat heute die Erweiterung der Liefervereinbarung mit Merck KGaA, Darmstadt, Germany und Pfizer Inc für Avelumab... go to the press release

---

Search: press release rcc

VAXIMM Announces First Results from Phase I/II Trial in Progressive Glioblastoma with Oral T-cell Immunotherapy VXM01 in Combination with PD-L1 Inhibitor Avelumab to be Presented at ASCO20 Virtual

• 2020-05-14
• Research / Development
• VAXIMM GmbH

. - Results from first nine patients include three objective responses - Two of these patients are progression-free >6 months - VXM01 in combination with avelumab was safe and produced specific immune responses - Results accepted for an oral presentation at conference VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies,... go to the press release

---

Search: press release rcc

Rapha Racing startet mit EFI Optitex 3D durch

• 2020-03-31
• Software
• EFI Germany

EFI™ Optitex®, globaler Anbieter von Electronics For Imaging für integrierte End-to-End-2D- und 3D-CAD/CAM-Softwarelösungen für die Mode- und Bekleidungsindustrie­, informierte heute über seine Vereinbarung mit Rapha® Racing Ltd., einem der weltweit führenden Premium-Hersteller für Radsportbekleidung. Im Rahmen der Vereinbarung erwarb Rapha Racing EFI... go to the press release

---

Search: press release rcc

Trimble gibt die Gewinner der Tekla Global BIM Awards 2018 bekannt

• 2018-09-27
• Software
• Trimble Solutions Germany GmbH

Trimble hat letzte Woche die Gewinner der Tekla BIM Awards 2018 bekanntgegeben. Der Wettbewerb findet alle zwei Jahre statt und kürt beeindruckende Bauprojekte basierend auf der Tekla BIM-Software (Building Information Modeling). Den Preis für das beste BIM-Projekt des Jahres 2018 erhält das Museum of the Future (Museum der Zukunft) in Dubai in den... go to the press release